NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Florian Guisier, Jaafar Bennouna, Alexander I. Spira, Dong-Wan Kim, Byoung Yong Shim, Houssein Abdul Sater, Italia Grenga, Swapnil S Parmar, Agata A. Bielska, Alula Yohannes, Raymond Mager, Oday Hamid, Lara McGrath, Yun He, Yee Soo-Hoo, Rakesh Kumar, Jonathan Spicer, Patrick M. Forde, Tina Cascone
Institutions: Centre Hospitalier Universitaire de Rouen, Centre Hospitalier Universitaire de Nantes, Virginia Cancer Specialists, Seoul National University, Seoul National University Hospital, The Catholic University of Korea St. Vincent's Hospital, Catholic University of Korea, Cleveland Clinic, AstraZeneca (United States), McGill University, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4379338170